{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T20:48:05Z","timestamp":1771015685039,"version":"3.50.1"},"reference-count":106,"publisher":"MDPI AG","issue":"24","license":[{"start":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:00:00Z","timestamp":1639612800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Portuguese League Against Cancer- Northern Branch (LPCC-NRN)","award":["Mod.PD.NRN.009.01"],"award-info":[{"award-number":["Mod.PD.NRN.009.01"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Increasing evidence has demonstrated the functional roles of miRNAs and lncRNAs in lymphoma onset and progression, either by acting as tumor-promoting ncRNAs or as tumor suppressors, emphasizing their appeal as lymphoma therapeutics. In fact, their intrinsic ability to modulate multiple dysregulated genes and\/or signaling pathways makes them an attractive therapeutic approach for a multifactorial pathology like lymphoma. Currently, the clinical application of miRNA- and lncRNA-based therapies still faces obstacles regarding effective delivery systems, off-target effects, and safety, which can be minimized with the appropriate chemical modifications and the development of tumor site-specific delivery approaches. Moreover, miRNA- and lncRNA-based therapeutics are being studied not only as monotherapies but also as complements of standard treatment regimens to provide a synergic effect, improving the overall treatment efficacy and reducing the therapeutic resistance. In this review, we summarize the fundamentals of miRNA- and lncRNA-based therapeutics by discussing the different types of delivery systems, with a focus on those that have been investigated in lymphoma in vitro and in vivo. Moreover, we described the ongoing clinical trials of novel miRNA- and lncRNA-based therapeutics in lymphoma.<\/jats:p>","DOI":"10.3390\/cancers13246324","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T11:27:36Z","timestamp":1639654056000},"page":"6324","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["miRNA- and lncRNA-Based Therapeutics for Non-Hodgkin\u2019s Lymphoma: Moving towards an RNA-Guided Precision Medicine"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9023-1109","authenticated-orcid":false,"given":"Mara","family":"Fernandes","sequence":"first","affiliation":[{"name":"Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Center (Porto.CCC), 4200-072 Porto, Portugal"},{"name":"Research Department of the Portuguese League against Cancer - Regional Nucleus of the North (LPCC-NRN), 4200-177 Porto, Portugal"},{"name":"Faculty of Medicine, University of Porto (FMUP), 4200-319 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5854-4444","authenticated-orcid":false,"given":"Herlander","family":"Marques","sequence":"additional","affiliation":[{"name":"Life and Health Sciences Research Institute (ICVS), School of Medicine, Campus de Gualtar, University of Minho, 4710-057 Braga, Portugal"},{"name":"ICVS\/3B\u2019s-PT Government Associate Laboratory, 4805-017 Braga\/Guimar\u00e3es, Portugal"},{"name":"Department of Oncology, Hospital de Braga, 4710-243 Braga, Portugal"},{"name":"CINTESIS, Center for Health Technology and Services Research, Faculty of Medicine, University of Porto, 4200-450 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7489-2211","authenticated-orcid":false,"given":"Ana Lu\u00edsa","family":"Teixeira","sequence":"additional","affiliation":[{"name":"Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Center (Porto.CCC), 4200-072 Porto, Portugal"},{"name":"ICBAS-Instituto de Ci\u00eancias Biom\u00e9dicas Abel Salazar, Universidade do Porto, 4050-513 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3010-8373","authenticated-orcid":false,"given":"Rui","family":"Medeiros","sequence":"additional","affiliation":[{"name":"Molecular Oncology and Viral Pathology Group, Research Center of IPO Porto (CI-IPOP)\/RISE@CI-IPOP (Health Research Network), Portuguese Oncology Institute of Porto (IPO Porto)\/Porto Comprehensive Cancer Center (Porto.CCC), 4200-072 Porto, Portugal"},{"name":"Research Department of the Portuguese League against Cancer - Regional Nucleus of the North (LPCC-NRN), 4200-177 Porto, Portugal"},{"name":"Faculty of Medicine, University of Porto (FMUP), 4200-319 Porto, Portugal"},{"name":"ICBAS-Instituto de Ci\u00eancias Biom\u00e9dicas Abel Salazar, Universidade do Porto, 4050-513 Porto, Portugal"},{"name":"Biomedical Research Center (CEBIMED), Faculty of Health Sciences of Fernando Pessoa University (UFP), 4249-004 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2010.33.3252","article-title":"Pathogenesis of Non-Hodgkin\u2019s Lymphoma","volume":"29","author":"Nogai","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"68","author":"Bray","year":"2018","journal-title":"CA A Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(16)32407-2","article-title":"Non-Hodgkin lymphoma","volume":"390","author":"Armitage","year":"2017","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Klener, P., and Klanova, M. (2020). Drug Resistance in Non-Hodgkin Lymphomas. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21062081"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00277-014-2271-1","article-title":"Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy","volume":"94","author":"Rovira","year":"2015","journal-title":"Ann. Hematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: Results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-019-0752-3","article-title":"Novel and emerging therapies for B cell lymphoma","volume":"12","author":"Ayyappan","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/d41573-019-00051-6","article-title":"Non-Hodgkin lymphoma therapy landscape","volume":"18","author":"Chaudhari","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrc.2017.99","article-title":"Non-coding RNA networks in cancer","volume":"18","author":"Anastasiadou","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"102825","DOI":"10.1016\/j.critrevonc.2019.102825","article-title":"The opportunistic effect of exosomes on Non-Hodgkin Lymphoma microenvironment modulation","volume":"144","author":"Fernandes","year":"2019","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd.2016.246","article-title":"MicroRNA therapeutics: Towards a new era for the management of cancer and other diseases","volume":"16","author":"Rupaimoole","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"15004","DOI":"10.1038\/sigtrans.2015.4","article-title":"The role of MicroRNAs in human cancer","volume":"1","author":"Peng","year":"2016","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Karstensen, K.T., Schein, A., Petri, A., B\u00f8gsted, M., Dybk\u00e6r, K., Uchida, S., and Kauppinen, S. (2021). Long Non-Coding RNAs in Diffuse Large B-Cell Lymphoma. Non-Coding RNA, 7.","DOI":"10.3390\/ncrna7010001"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.cell.2018.01.011","article-title":"Functional Classification and Experimental Dissection of Long Noncoding RNAs","volume":"172","author":"Kopp","year":"2018","journal-title":"Cell"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41580-020-00315-9","article-title":"Gene regulation by long non-coding RNAs and its biological functions","volume":"22","author":"Statello","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.ebiom.2016.09.017","article-title":"microRNA Therapeutics in Cancer\u2014An Emerging Concept","volume":"12","author":"Shah","year":"2016","journal-title":"EBioMedicine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/nature06783","article-title":"LNA-mediated microRNA silencing in non-human primates","volume":"452","author":"Lindow","year":"2008","journal-title":"Nature"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.addr.2014.09.002","article-title":"Small molecule compounds targeting miRNAs for cancer therapy","volume":"81","author":"Monroig","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/nature04303","article-title":"Silencing of microRNAs in vivo with \u2018antagomirs\u2019","volume":"438","author":"Rajewsky","year":"2005","journal-title":"Nature"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s41544-019-0024-y","article-title":"Recent progress in microRNA-based delivery systems for the treatment of human disease","volume":"1","author":"Fu","year":"2019","journal-title":"ExRNA"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.addr.2014.05.009","article-title":"In vivo delivery of miRNAs for cancer therapy: Challenges and strategies","volume":"81","author":"Chen","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1016\/j.cell.2009.04.021","article-title":"Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model","volume":"137","author":"Kota","year":"2009","journal-title":"Cell"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1002\/nbm.1416","article-title":"Evidence for in vivo macrophage mediated tumor uptake of paramagnetic\/fluorescent liposomes","volume":"22","author":"Castelli","year":"2009","journal-title":"NMR Biomed."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.2217\/nmt-2018-0033","article-title":"Patisiran, an RNAi therapeutic for the treatment of hereditary transthyretin-mediated amyloidosis","volume":"9","author":"Kristen","year":"2019","journal-title":"Neurodegener. Dis. Manag."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/carcin\/bgz183","article-title":"miR-155 as a novel clinical target for hematological malignancies","volume":"41","author":"Witten","year":"2019","journal-title":"Carcinogenesis"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1038\/leu.2012.110","article-title":"Systemic microRNA-34a delivery induces apoptosis and abrogates growth of diffuse large B-cell lymphoma in vivo","volume":"26","author":"Craig","year":"2012","journal-title":"Leukemia"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Di Martino, M.T., Campani, V., Misso, G., Gallo Cantafio, M.E., Gull\u00e0, A., Foresta, U., Guzzi, P.H., Castellano, M., Grimaldi, A., and Gigantino, V. (2014). In vivo activity of miR-34a mimics delivered by stable nucleic acid lipid particles (SNALPs) against multiple myeloma. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0090005"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"6260","DOI":"10.1158\/1078-0432.CCR-12-1708","article-title":"Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: In vitro and in vivo evidence","volume":"18","author":"Leone","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1182\/blood-2012-02-410647","article-title":"LNA-mediated anti\u2013miR-155 silencing in low-grade B-cell lymphomas","volume":"120","author":"Zhang","year":"2012","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nature13905","article-title":"MicroRNA silencing for cancer therapy targeted to the tumour microenvironment","volume":"518","author":"Cheng","year":"2015","journal-title":"Nature"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"E1695","DOI":"10.1073\/pnas.1201516109","article-title":"Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma","volume":"109","author":"Babar","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/gene.2011.58","article-title":"Systemic in vivo lentiviral delivery of miR-15a\/16 reduces malignancy in the NZB de novo mouse model of chronic lymphocytic leukemia","volume":"13","author":"Kasar","year":"2012","journal-title":"Genes Immun."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1158\/2326-6066.CIR-15-0161","article-title":"A Critical Role of miR-144 in Diffuse Large B-cell Lymphoma Proliferation and Invasion","volume":"4","author":"Wang","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1038\/s41388-017-0055-5","article-title":"Activating and sustaining c-Myc by depletion of miR-144\/451 gene locus contributes to B-lymphomagenesis","volume":"37","author":"Ding","year":"2018","journal-title":"Oncogene"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"9832956","DOI":"10.1155\/2019\/9832956","article-title":"MicroRNA-181a Inhibits Activated B-Cell-Like Diffuse Large B-Cell Lymphoma Progression by Repressing CARD11","volume":"2019","author":"Zhu","year":"2019","journal-title":"J. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"2856","DOI":"10.1182\/blood-2015-11-680462","article-title":"miR-181a negatively regulates NF-\u03baB signaling and affects activated B-cell\u2013like diffuse large B-cell lymphoma pathogenesis","volume":"127","author":"Kozloski","year":"2016","journal-title":"Blood"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/leu.2017.299","article-title":"HDAC6 regulates microRNA-27b that suppresses proliferation, promotes apoptosis and target MET in diffuse large B-cell lymphoma","volume":"32","author":"Jia","year":"2018","journal-title":"Leukemia"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1182\/blood-2016-08-731166","article-title":"miR-28 regulates the germinal center reaction and blocks tumor growth in preclinical models of non-Hodgkin lymphoma","volume":"129","author":"Mur","year":"2017","journal-title":"Blood"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1158\/1078-0432.CCR-12-3325","article-title":"Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth","volume":"19","author":"Leone","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"49143","DOI":"10.18632\/oncotarget.9237","article-title":"Therapeutic strategy with artificially-designed i-lncRNA targeting multiple oncogenic microRNAs exhibits effective antitumor activity in diffuse large B-cell lymphoma","volume":"7","author":"Su","year":"2016","journal-title":"Oncotarget"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1038\/s41467-018-04791-8","article-title":"Efficient RNA drug delivery using red blood cell extracellular vesicles","volume":"9","author":"Usman","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1038\/onc.2009.445","article-title":"Regression of murine lung tumors by the let-7 microRNA","volume":"29","author":"Trang","year":"2010","journal-title":"Oncogene"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/1477-3155-9-40","article-title":"Nanoparticle-based delivery of siDCAMKL-1 increases microRNA-144 and inhibits colorectal cancer tumor growth via a Notch-1 dependent mechanism","volume":"9","author":"Sureban","year":"2011","journal-title":"J. Nanobiotechnol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1093\/nar\/gkl183","article-title":"Improved targeting of miRNA with antisense oligonucleotides","volume":"34","author":"Davis","year":"2006","journal-title":"Nucleic Acids Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV Infection by Targeting MicroRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.addr.2014.10.031","article-title":"Recent progress in microRNA delivery for cancer therapy by non-viral synthetic vectors","volume":"81","author":"Wang","year":"2015","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Dasgupta, I., and Chatterjee, A. (2021). Recent Advances in miRNA Delivery Systems. Methods Protoc., 4.","DOI":"10.3390\/mps4010010"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/wnan.1228","article-title":"Polyethylenimines for siRNA and miRNA delivery in vivo","volume":"5","author":"Aigner","year":"2013","journal-title":"Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/cbin.10157","article-title":"Design of polyethylene glycol\u2013polyethylenimine nanocomplexes as non-viral carriers: Mir-150 delivery to chronic myeloid leukemia cells","volume":"37","year":"2013","journal-title":"Cell Biol. Int."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1021\/acs.accounts.6b00506","article-title":"Surface Modification of Gold Nanoparticles with Small Molecules for Biochemical Analysis","volume":"50","author":"Chen","year":"2017","journal-title":"Acc. Chem. Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"10710","DOI":"10.3390\/ijms140610710","article-title":"Innovative strategy for microRNA delivery in human mesenchymal stem cells via magnetic nanoparticles","volume":"14","author":"Schade","year":"2013","journal-title":"Int. J. Mol. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1021\/acs.accounts.0c00280","article-title":"Silica-Based Nanoparticles for Biomedical Applications: From Nanocarriers to Biomodulators","volume":"53","author":"Yang","year":"2020","journal-title":"Acc. Chem. Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12951-018-0392-8","article-title":"Nano based drug delivery systems: Recent developments and future prospects","volume":"16","author":"Patra","year":"2018","journal-title":"J. Nanobiotechnol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.biomaterials.2012.10.023","article-title":"A gold nanoparticle platform for the delivery of functional microRNAs into cancer cells","volume":"34","author":"Ghosh","year":"2013","journal-title":"Biomaterials"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"5348","DOI":"10.1038\/s41598-019-41866-y","article-title":"Multifunctional Gold Nanoparticles Overcome MicroRNA Regulatory Network Mediated-Multidrug Resistant Leukemia","volume":"9","author":"Deng","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1007\/s11481-019-09873-y","article-title":"Strategies for the use of Extracellular Vesicles for the Delivery of Therapeutics","volume":"15","author":"Sil","year":"2020","journal-title":"J. Neuroimmune Pharmacol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1186\/s12943-021-01431-6","article-title":"Application of the CRISPR\/Cas9-based gene editing technique in basic research, diagnosis, and therapy of cancer","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Nguyen, D.-D., and Chang, S. (2017). Development of Novel Therapeutic Agents by Inhibition of Oncogenic MicroRNAs. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19010065"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1080\/15476286.2014.996067","article-title":"Small indels induced by CRISPR\/Cas9 in the 5\u2032 region of microRNA lead to its depletion and Drosha processing retardance","volume":"11","author":"Jiang","year":"2014","journal-title":"RNA Biol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1038\/srep03943","article-title":"Sequence-specific inhibition of microRNA via CRISPR\/CRISPRi system","volume":"4","author":"Zhao","year":"2014","journal-title":"Sci. Rep."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"22312","DOI":"10.1038\/srep22312","article-title":"CRISPR\/cas9, a novel genomic tool to knock down microRNA in vitro and in vivo","volume":"6","author":"Chang","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"32386","DOI":"10.1038\/srep32386","article-title":"In vivo mutagenesis of miRNA gene families using a scalable multiplexed CRISPR\/Cas9 nuclease system","volume":"6","author":"Narayanan","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2147\/CMAR.S34273","article-title":"Treatment challenges in the management of relapsed or refractory non-Hodgkin\u2019s lymphoma\u2014Novel and emerging therapies","volume":"5","author":"Chao","year":"2013","journal-title":"Cancer Manag. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"83987","DOI":"10.18632\/oncotarget.9793","article-title":"Relapsed diffuse large B-cell lymphoma present different genomic profiles between early and late relapses","volume":"7","author":"Broseus","year":"2016","journal-title":"Oncotarget"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1177\/1535370213498985","article-title":"Non-Hodgkin\u2019s B-cell lymphoma: Advances in molecular strategies targeting drug resistance","volume":"238","author":"Maxwell","year":"2013","journal-title":"Exp. Biol. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s12185-012-1256-x","article-title":"MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen","volume":"97","author":"Bai","year":"2013","journal-title":"Int. J. Hematol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"18077","DOI":"10.3390\/ijms160818077","article-title":"miR-199a and miR-497 are Associated with Better Overall Survival due to Increased Chemosensitivity in Diffuse Large B-Cell Lymphoma Patients","volume":"16","author":"Troppan","year":"2015","journal-title":"Int. J. Mol. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.exphem.2015.12.007","article-title":"High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma","volume":"44","author":"Marques","year":"2016","journal-title":"Exp. Hematol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.3892\/ol.2016.4313","article-title":"MicroRNA-187 induces diffuse large B-cell lymphoma cell apoptosis via targeting BCL6","volume":"11","author":"Huang","year":"2016","journal-title":"Oncol. Lett."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1038\/s41408-017-0033-8","article-title":"MicroRNAs regulate key cell survival pathways and mediate chemosensitivity during progression of diffuse large B-cell lymphoma","volume":"7","author":"Leivonen","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s12967-018-1537-0","article-title":"Clinicopathologic implication of microRNA-197 in diffuse large B cell lymphoma","volume":"16","author":"Yang","year":"2018","journal-title":"J. Transl. Med."},{"key":"ref_73","first-page":"1058","article-title":"MicroRNA-497 inhibits multiple myeloma growth and increases susceptibility to bortezomib by targeting Bcl-2","volume":"43","author":"Tian","year":"2019","journal-title":"Int. J. Mol. Med."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/ijc.31041","article-title":"MicroRNA-324-5p regulates stemness, pathogenesis and sensitivity to bortezomib in multiple myeloma cells by targeting hedgehog signaling","volume":"142","author":"Tang","year":"2018","journal-title":"Int. J. Cancer"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"15035","DOI":"10.18632\/oncotarget.3729","article-title":"MicroRNA-21 plays an oncogenic role by targeting FOXO1 and activating the PI3K\/AKT pathway in diffuse large B-cell lymphoma","volume":"6","author":"Go","year":"2015","journal-title":"Oncotarget"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.3109\/10428194.2012.659736","article-title":"Epstein\u2013Barr virus latent membrane protein-1 protects B-cell lymphoma from rituximab-induced apoptosis through miR-155-mediated Akt activation and up-regulation of Mcl-1","volume":"53","author":"Kim","year":"2012","journal-title":"Leuk. Lymphoma."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.biopha.2018.06.093","article-title":"Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin","volume":"106","author":"Sun","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1093\/jrr\/rrs002","article-title":"MicroRNA-148b enhances the radiosensitivity of non-Hodgkin\u2019s Lymphoma cells by promoting radiation-induced apoptosis","volume":"53","author":"Wu","year":"2012","journal-title":"J. Radiat. Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13046-017-0639-5","article-title":"MicroRNA-150 enhances radiosensitivity by inhibiting the AKT pathway in NK\/T cell lymphoma","volume":"37","author":"Wu","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.apsb.2020.10.001","article-title":"Long non-coding RNAs: From disease code to drug role","volume":"11","author":"Chen","year":"2021","journal-title":"Acta. Pharm. Sin. B."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"116335","DOI":"10.1016\/j.lfs.2019.03.040","article-title":"LncRNA MALAT1 promotes tumorigenesis and immune escape of diffuse large B cell lymphoma by sponging miR-195","volume":"231","author":"Wang","year":"2019","journal-title":"Life Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nbt.3802","article-title":"Overcoming cellular barriers for RNA therapeutics","volume":"35","author":"Dowdy","year":"2017","journal-title":"Nat. Biotechnol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"5845","DOI":"10.2147\/CMAR.S248698","article-title":"Knockdown of lncRNA MCM3AP-AS1 Attenuates Chemoresistance of Burkitt Lymphoma to Doxorubicin Treatment via Targeting the miR-15a\/EIF4E Axis","volume":"12","author":"Guo","year":"2020","journal-title":"Cancer Manag. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11010-019-03588-7","article-title":"Downregulation of long non-coding RNA TUG1 suppresses tumor growth by promoting ubiquitination of MET in diffuse large B-cell lymphoma","volume":"461","author":"Cheng","year":"2019","journal-title":"Mol. Cell. Biochem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1093\/nar\/gkv1206","article-title":"Cellular localization of long non-coding RNAs affects silencing by RNAi more than by antisense oligonucleotides","volume":"44","author":"Lennox","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.neuron.2017.04.010","article-title":"Antisense Oligonucleotides: Translation from Mouse Models to Human Neurodegenerative Diseases","volume":"94","author":"Schoch","year":"2017","journal-title":"Neuron"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41375-019-0542-5","article-title":"Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma","volume":"34","author":"Taiana","year":"2020","journal-title":"Leukemia"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1093\/nar\/gku1198","article-title":"Targeting non-coding RNAs with the CRISPR\/Cas9 system in human cell lines","volume":"43","author":"Ho","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1038\/nbt.3715","article-title":"Genome-scale deletion screening of human long non-coding RNAs using a paired-guide RNA CRISPR\u2013Cas9 library","volume":"34","author":"Zhu","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41375-020-01034-y","article-title":"The long non-coding RNA CRNDE regulates growth of multiple myeloma cells via an effect on IL6 signalling","volume":"35","author":"David","year":"2021","journal-title":"Leukemia"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.cell.2013.02.022","article-title":"Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression","volume":"152","author":"Qi","year":"2013","journal-title":"Cell"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"6571","DOI":"10.1073\/pnas.1921786117","article-title":"An MXD1-derived repressor peptide identifies noncoding mediators of MYC-driven cell proliferation","volume":"117","author":"Raffeiner","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_93","first-page":"e12","article-title":"Challenges of CRISPR\/Cas9 applications for long non-coding RNA genes","volume":"45","author":"Goyal","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1177\/1087057115594187","article-title":"Screening for Small-Molecule Modulators of Long Noncoding RNA-Protein Interactions Using AlphaScreen","volume":"20","author":"Modarresi","year":"2015","journal-title":"J. Biomol. Screen."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1021\/acschembio.8b00807","article-title":"Selective Small-Molecule Targeting of a Triple Helix Encoded by the Long Noncoding RNA, MALAT1","volume":"14","author":"Abulwerdi","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.canlet.2019.10.026","article-title":"Small molecule inhibition of Ewing sarcoma cell growth via targeting the long non coding RNA HULC","volume":"469","author":"Mercatelli","year":"2020","journal-title":"Cancer Lett."},{"key":"ref_97","unstructured":"(2021, June 03). A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01829971."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"122","author":"Hong","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_99","unstructured":"(2021, June 03). MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLC, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02369198."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2217\/epi-2016-0035","article-title":"Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer","volume":"8","author":"Reid","year":"2016","journal-title":"Epigenomics"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1016\/S1470-2045(17)30621-6","article-title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: A first-in-man, phase 1, open-label, dose-escalation study","volume":"18","author":"Pavlakis","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_102","unstructured":"(2021, June 03). Safety, Tolerability and Pharmacokinetics of MRG-106 in Patients With Mycosis Fungoides (MF), CLL, DLBCL or ATLL, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02580552."},{"key":"ref_103","unstructured":"(2021, June 03). PRISM: Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Mycosis Fungoides Who Have Completed the SOLAR Study, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03837457."},{"key":"ref_104","unstructured":"(2021, June 03). SOLAR: Efficacy and Safety of Cobomarsen (MRG-106) vs. Active Comparator in Subjects With Mycosis Fungoides, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03713320."},{"key":"ref_105","unstructured":"(2021, June 03). Phase 1 Safety and Tolerability Study of Andes-1537 for Injection in Patients With Advanced Unresectable Solid Tumors, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02508441."},{"key":"ref_106","unstructured":"(2021, June 03). Study With Andes-1537 in Patients With Specific Types of Advanced Solid Tumor, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03985072."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/24\/6324\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:49:59Z","timestamp":1760168999000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/13\/24\/6324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,16]]},"references-count":106,"journal-issue":{"issue":"24","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["cancers13246324"],"URL":"https:\/\/doi.org\/10.3390\/cancers13246324","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,16]]}}}